The estimated Net Worth of Merz Cathleen Noel Bairey is at least $879 mil dollars as of 12 September 2022. Merz Bairey owns over 90 units of iRhythm Technologies Inc stock worth over $365,694 and over the last 7 years Merz sold IRTC stock worth over $513,548.
Merz has made over 4 trades of the iRhythm Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Merz sold 90 units of IRTC stock worth $14,379 on 12 September 2022.
The largest trade Merz's ever made was selling 2,804 units of iRhythm Technologies Inc stock on 1 June 2020 worth over $350,921. On average, Merz trades about 354 units every 91 days since 2018. As of 12 September 2022 Merz still owns at least 4,887 units of iRhythm Technologies Inc stock.
You can see the complete history of Merz Bairey stock trades at the bottom of the page.
Merz's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO, CA, 94103.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi y Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: